<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2016.61004</article-id><article-id pub-id-type="publisher-id">ACM-17069</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20160100000_95166689.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  非小细胞肺癌分子靶向治疗研究进展
  Research Progress of Molecular Target Therapy in Non-Small Cell Lung Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>琨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>寿</surname><given-names>伟臻</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>上海中医药大学，上海</addr-line></aff><aff id="aff3"><addr-line>上海中医药大学附属龙华医院，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>01</month><year>2016</year></pub-date><volume>06</volume><issue>01</issue><fpage>17</fpage><lpage>22</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   肺癌是一种发病率、病死率均较高的恶性肿瘤，临床上多采用手术、放疗、化疗等治疗手段，但是不得不承认的是，除了对于早期肺癌及体质较好的患者有较为可观的疗效外，其治疗效果的上升空间相对局限。肺癌分子靶向治疗与传统的手术、放疗、化疗相比，因其与肿瘤细胞上特有的靶点产生特异性结合，精确打击肿瘤细胞而又不伤害正常的细胞，从而具有毒副反应较小的优点，这种新的治疗方式提高了患者的生活质量。本文对肺癌生物靶向治疗药物的研究进展进行综述。 Lung cancer is a malignant tumor with high incidence rate and mortality rate. Clinically, treatment means, like surgery, radiotherapy, chemotherapy treatment, etc. are used. However, it had to admit that, besides the considerable effect for patients with early lung cancer and patients with good physique, the rising space of the treatment effect relatively limited. Lung cancer molecular target-ing therapy, compared with traditional surgery, radiotherapy and chemotherapy, due to its specific binding to the specific target of tumor cells, precisely attacking tumor cells without harm to the normal cells, has got the advantage of less toxic side effect. This new treatment modality improves patients’ life quality. This paper reviewed the research progress of drug treatment to lung cancer biological target.
    
  
 
</p></abstract><kwd-group><kwd>非小细胞肺癌，靶向治疗，研究进展, Non-Small Cell Lung Cancer</kwd><kwd> Targeted Therapy</kwd><kwd> Research Progress</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>非小细胞肺癌分子靶向治疗研究进展<sup> </sup></title><p>张琨<sup>1</sup>，寿伟臻<sup>2</sup></p><p><sup>1</sup>上海中医药大学，上海</p><p><sup>2</sup>上海中医药大学附属龙华医院，上海</p><disp-formula id="hanspub.17069-formula37"><graphic xlink:href="http://html.hanspub.org/file/4-1570190x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年2月11日；录用日期：2016年2月29日；发布日期：2016年3月3日</p><disp-formula id="hanspub.17069-formula38"><graphic xlink:href="http://html.hanspub.org/file/4-1570190x7_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>肺癌是一种发病率、病死率均较高的恶性肿瘤，临床上多采用手术、放疗、化疗等治疗手段，但是不得不承认的是，除了对于早期肺癌及体质较好的患者有较为可观的疗效外，其治疗效果的上升空间相对局限。肺癌分子靶向治疗与传统的手术、放疗、化疗相比，因其与肿瘤细胞上特有的靶点产生特异性结合，精确打击肿瘤细胞而又不伤害正常的细胞，从而具有毒副反应较小的优点，这种新的治疗方式提高了患者的生活质量。本文对肺癌生物靶向治疗药物的研究进展进行综述。</p><p>关键词 :非小细胞肺癌，靶向治疗，研究进展</p><disp-formula id="hanspub.17069-formula39"><graphic xlink:href="http://html.hanspub.org/file/4-1570190x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>肺癌是世界范围内最常见的恶性肿瘤，其死亡数几乎占所有癌症死亡数的30%左右 [<xref ref-type="bibr" rid="hanspub.17069-ref1">1</xref>] 。近几年，随着社会工业化进程不断扩大，空气污染日益严重，雾霾频发，肺癌的发病率呈现出持续增长的态势 [<xref ref-type="bibr" rid="hanspub.17069-ref2">2</xref>] 。我国目前每年新诊出肺癌患者数约50万例，预计到2025年每年将新诊出100万例肺癌患者 [<xref ref-type="bibr" rid="hanspub.17069-ref3">3</xref>] 。其中80%~85%为非小细胞肺癌(Non-Small Cell Lung Cancer, NSCLC) [<xref ref-type="bibr" rid="hanspub.17069-ref4">4</xref>] 。</p><p>目前手术治疗为控制肺部肿瘤原发灶及转移灶最有效的方法，但因肿瘤发现的时候一般都处于晚期，故手术治疗很难达到理想疗效，仅有1/3左右的NSCLC患者可行根治性手术 [<xref ref-type="bibr" rid="hanspub.17069-ref5">5</xref>] 。传统的放疗、化疗及免疫治疗对肿瘤细胞的选择性差，在消灭肿瘤细胞的同时对机体的正常细胞也造成一定的伤害，从而引起各种不良反应 [<xref ref-type="bibr" rid="hanspub.17069-ref6">6</xref>] 。治疗手段虽然在不断增加，但肺癌的发病率和死亡率却迅速上升，现已经跃居各恶性肿瘤第一位，且5年生存率仍低于5% [<xref ref-type="bibr" rid="hanspub.17069-ref7">7</xref>] 。因此急需探索一种针对肺癌的新的有效的治疗方法。近年来，癌症的靶向治疗逐渐成为研究热点，治疗效果也有目共睹。笔者查阅了近年来国内外NSCLC靶向治疗的药物研究进展做如下综述。</p></sec><sec id="s4"><title>2. 抑制肿瘤血管新生</title><p>肿瘤血管在肿瘤的发生、发展以及转移中扮演着重要的角色。肿瘤有诱导血管生成的能力，肿瘤直径达到1~2 mm后，若无新生血管生成提供营养，肿瘤就停止生长。肿瘤细胞能产生血管生成因子，血管生成因子与其受体结合后，可促进血管内皮细胞分裂和毛细血管出芽生长。血管生成在肿瘤的形成、生长、侵袭和转移中起着十分重要的作用。以肿瘤血管为靶点的治疗药物主要包括贝伐单抗、血管内皮抑制素。</p><sec id="s4_1"><title>2.1. 贝伐单抗(Bevacizumab)</title><p>贝伐单抗是一种重组的人源化单克隆抗体，可与血管内皮生长因子受体结合，阻碍VEGF与其受体在内皮细胞表面相互作用。它于2006年10月第1个被美国FDA批准用于癌症治疗的抗血管生成药物 [<xref ref-type="bibr" rid="hanspub.17069-ref8">8</xref>] 。贝伐珠单抗单药治疗NSCLC效果不好，但是与各种化疗方案联合可显著提高化疗的治疗效果 [<xref ref-type="bibr" rid="hanspub.17069-ref9">9</xref>] 。Johnson等 [<xref ref-type="bibr" rid="hanspub.17069-ref10">10</xref>] 的研究中，随机对比PC方案与PC方案联合贝伐单抗即PCB方案一线治疗晚期NSCLC。PCB方案均优于PC方案。Reck等 [<xref ref-type="bibr" rid="hanspub.17069-ref11">11</xref>] 进行的一项吉西他滨加顺铂方案联合安慰剂或贝伐单抗治疗NSCLC的III期临床实验。该实验表明对进展期NSCLC吉西他滨加顺铂方案联合贝伐单抗可显著提高无进展生存期和客观有效率。Heist等 [<xref ref-type="bibr" rid="hanspub.17069-ref12">12</xref>] 进行的一项多中心的奥沙利铂、培美曲塞和贝伐单抗三药联合治疗非NSCLC前瞻性II期研究。这项前瞻性研究结论表明奥沙利铂、培美曲塞联合靶向治疗药物贝伐单抗治疗经治的进展期NSCLC疗效较好，不良反应可耐受。据王艇等 [<xref ref-type="bibr" rid="hanspub.17069-ref13">13</xref>] 的临床试验研究，贝伐单抗与PC方案连用治疗晚期非鳞状NSCLC能够有效提高有效率、中位生存期和疾病进展时间，从而比单纯PC方案更适合患者。</p></sec><sec id="s4_2"><title>2.2. 血管内皮抑制素(恩度，Endostar)</title><p>恩度 [<xref ref-type="bibr" rid="hanspub.17069-ref14">14</xref>] 是我国研发的抗肿瘤血管形成靶向治疗新药，其与化疗联合在NSCLC的疗效确切，已被NCCN中NSCLC临床实践指南中国版收入。其主要通过降低内皮细胞活性而抑制血管内皮生长因子等的生成及活性，具有较好的临床疗效，可有效延长肿瘤患者生存期 [<xref ref-type="bibr" rid="hanspub.17069-ref15">15</xref>] 。郑青平等 [<xref ref-type="bibr" rid="hanspub.17069-ref16">16</xref>] 在临床试验中发现VEGF或微血管生成标志CD34异常高表达时，应用恩度的疗效较好，而当VEGF或CD34低表达，这类病例抗血管形成策略或许不是最佳选择。</p></sec></sec><sec id="s5"><title>3. EGFR酪氨酸激酶抑制剂</title><p>EGFR是原癌基因的表达产物，定位于细胞膜上。EGFR家族是由4个结构相似的酪氨酸激酶受体组成，分别是EGFR/c-ErbB1/EGFR1，c-ErbB2/HER2，c-ErbB3/HER3，c-ErbB4/HER4。有研究 [<xref ref-type="bibr" rid="hanspub.17069-ref17">17</xref>] 表明，在NSCLC中表皮生长因子受体(EGFR)的阳性表达率为53.1%~69.7%。而过高的EGFR表达导致NSCLC对常规的化疗药物(顺铂等)不敏感 [<xref ref-type="bibr" rid="hanspub.17069-ref18">18</xref>] 。</p><sec id="s5_1"><title>3.1. 小分子络氨酸激酶抑制剂(TKI)</title><sec id="s5_1_1"><title>3.1.1. 吉非替尼(Gefitinib)</title><p>吉非替尼为首个口服EGFR-TKI，适用于接受化疗、放疗或激素治疗后而效果并不明显的肿瘤患者及局部晚期非小细胞肺癌患者，其主要通过抑制肿瘤血管形成而抑制肿瘤细胞生长、促进肿瘤细胞凋亡。据刘赞等 [<xref ref-type="bibr" rid="hanspub.17069-ref19">19</xref>] 的临床实验结果，吉非替尼是治疗晚期NSCLC的有效药物，对脑转移患者仍可取得较好效果。KirS等 [<xref ref-type="bibr" rid="hanspub.17069-ref20">20</xref>] 研究吉非替尼三线或三线以上治疗NSCLC中，对吉非替尼的回顾性研究显示不吸烟者、女性、支气管肺泡癌或腺癌伴支气管肺泡癌分化者有效率高 [<xref ref-type="bibr" rid="hanspub.17069-ref21">21</xref>] 。Seqiust等 [<xref ref-type="bibr" rid="hanspub.17069-ref22">22</xref>] 进行了有关EGFR基因突变与吉非替尼治疗进展期NSCLC疗效之间的多中心、前瞻性研究。结果显示，吉非替尼联合标准化疗方案用于进展期存在EGFR基因突变NSCLC的治疗是有效的。Zhu等 [<xref ref-type="bibr" rid="hanspub.17069-ref23">23</xref>] 的研究表明19号外显子上的缺失突变患者的生存期长于21号外显子点突变的患者，提示我们在做吉非替尼的治疗决策时要根据EGFR基因突变情况而不仅仅是EGFR的表达。</p></sec><sec id="s5_1_2"><title>3.1.2. 厄洛替尼(Erlotinib)</title><p>厄罗替尼是一种I型表皮生长因子受体酪氨酸激酶抑制剂。Akelrey等 [<xref ref-type="bibr" rid="hanspub.17069-ref24">24</xref>] 进行的一项评估厄罗替尼用于一线治疗经过严格筛选的、未化疗的NSCLC患者的疗效。结果显示可延长晚期NSCLC患者的生存期，推荐厄罗替尼作为进展期NSCLC的一线治疗。Costa等 [<xref ref-type="bibr" rid="hanspub.17069-ref25">25</xref>] 进行的回顾性研究表明，吉非替尼和厄罗替尼具有交叉耐药性，对吉非替尼耐药的NSCLC患者对厄罗替尼大多耐药，增加剂量并不能克服耐药性。Shepherd等 [<xref ref-type="bibr" rid="hanspub.17069-ref26">26</xref>] 进行的大型随机对照Ⅲ期试验(BR21试验)中显示出生存优势，该药于2004年11月被美国批准用于治疗铂类化疗失败后晚期NSCLC，并于2007年进入国内市场 [<xref ref-type="bibr" rid="hanspub.17069-ref27">27</xref>] 。另有研究者应用厄洛替尼与一线化疗药物联合治疗晚期NSCLC，发现并不增加疗效，所以不推荐联合用药 [<xref ref-type="bibr" rid="hanspub.17069-ref28">28</xref>] 。</p></sec></sec><sec id="s5_2"><title>3.2. 单克隆抗体</title>西妥昔单抗(Cetuximab, C225)<p>西妥昔单抗是一重组的人鼠嵌合EGFR的单克隆抗体，可以高度特异地与EGFR结合。已被证实对NSCLC、头颈部癌和结肠癌等多种肿瘤有效 [<xref ref-type="bibr" rid="hanspub.17069-ref29">29</xref>] 。Belain等 [<xref ref-type="bibr" rid="hanspub.17069-ref30">30</xref>] 进行了一项西妥昔单抗联合多西他赛和顺铂治疗进展NSCLC多中心的11期研究，结论显示西妥昔单抗联合多西他赛加顺铂方案治疗进展期NSCLC具有中等度的有效性和可耐受的不良反应。iPrker等 [<xref ref-type="bibr" rid="hanspub.17069-ref31">31</xref>] 进行了一项西妥昔单抗一线治疗进展期NSCLC的研究，亦取得了较高的有效率。</p></sec></sec><sec id="s6"><title>4. 多靶点治疗</title><sec id="s6_1"><title>4.1. 索拉非尼(Sorafenib)</title><p>索拉菲尼是一种新型激酶信号传导抑制剂，可以阻断丝氨酸/苏氨酸激酶(RAF激酶)、VEGFR-2、VEGFR-3、PDGFR-β、c-Kit和Fit-3 [<xref ref-type="bibr" rid="hanspub.17069-ref32">32</xref>] 。Stewar等 [<xref ref-type="bibr" rid="hanspub.17069-ref33">33</xref>] 进行了索拉非尼联合厄罗替尼治疗NSCLCll期临床研究，结果显示2种靶向药物联合应用取得了较高的有效率。Escape研究 [<xref ref-type="bibr" rid="hanspub.17069-ref34">34</xref>] 比较了PC方案或其联合索拉非尼用于NSCLC的一线治疗的临床疗效，结果却发现NSCLC患者的OR、PFS、OS并未因为联合索拉非尼而有明显改善，且鳞癌患者接受联合治疗其PFS、OS均显著低于单纯化疗组，提示鳞癌患者可能并不适合接受索拉非尼治疗。临床上常用于部分实体肿瘤的治疗，包括肺癌、肾癌、肝癌等。</p></sec><sec id="s6_2"><title>4.2. 舒尼替尼(Sunitinib, SU11248)</title><p>舒尼替尼是一种口服的小分子酪氨酸激酶抑制剂，是目前已知的作用靶点最多的靶向抗肿瘤药物之一，具有广谱的抗肿瘤活性 [<xref ref-type="bibr" rid="hanspub.17069-ref35">35</xref>] 。Socinsik进行了一项舒尼替尼治疗经治的NSCLC的多中心、II期临床试验，结果显示舒尼替尼单药治疗复发进展的NSCLC与其他已批准的靶向药物疗效相似，不良反应更低 [<xref ref-type="bibr" rid="hanspub.17069-ref36">36</xref>] 。一项Ⅱ期临床试验显示，舒尼替尼组的目标缓解率和无疾病进展生存期和中位生存期明显高于对照组，说明舒尼替尼有较好的抗肿瘤效果 [<xref ref-type="bibr" rid="hanspub.17069-ref37">37</xref>] 。临床上主要用于肺癌、胃肠道间质瘤、肾癌的治疗。</p></sec><sec id="s6_3"><title>4.3. 凡德他尼(Vandetanib, ZD6474)</title><p>凡德他尼是一种合成的苯胺喹唑啉化合物，为口服的小分子酪氨酸激酶抑制剂(TKI)，可同时作用于肿瘤细胞表皮生长因子受体(EGFR)、血管内皮生长因子受体(VEG-FR)及RET酪氨酸激酶 [<xref ref-type="bibr" rid="hanspub.17069-ref38">38</xref>] 。李梦君等 [<xref ref-type="bibr" rid="hanspub.17069-ref39">39</xref>] 对NSCLC的分析研究证明，凡德他尼治疗晚期NSCLC患者可以提高患者的无疾病进展生存期，但对患者的总生存率无明显改善，而在延缓症状的恶化中可能具有一定的效果。Natale等 [<xref ref-type="bibr" rid="hanspub.17069-ref40">40</xref>] 对168例晚期NSCLC患者进行凡德他尼和吉非替尼疗效对比试验发现，凡德他尼组明显延长无疾病进展生存期。目前临床上主要用于肺癌、甲状腺癌等。</p></sec></sec><sec id="s7"><title>5. 小结与展望</title><p>肺癌靶向治疗是一种新型癌症治疗方法，因其有效性而受到患者及医生青睐，但是不是所有肿瘤患者都可以口服靶向药物进行治疗，靶向药物只适用于特定基因突变患者。另外靶向药物治疗一段时间患者会产生耐药性，极大限制了分子靶向药物的应用。好在有条件单位已开展预测化疗药物和靶向剂疗效的基因组学鉴定，成为肿瘤个体治化治疗的技术革命，通过对个病人具体基因组学特征的确定，制定相应合适的放化疗加靶向治疗方案，以取得最佳的治疗效果。相信随着广大医务工作者及药品研发工作者的不断努力及深入研究，肺癌靶向治疗及相关治疗药物方面的研究定会取得重大突破与进展。</p></sec><sec id="s8"><title>文章引用</title><p>张 琨,寿伟臻. 非小细胞肺癌分子靶向治疗研究进展Research Progress of Molecular Target Therapy in Non-Small Cell Lung Cancer[J]. 临床医学进展, 2016, 06(01): 17-22. http://dx.doi.org/10.12677/ACM.2016.61004</p></sec><sec id="s9"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.17069-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Pakkala, S. and Ramalingam, S.S. (2009) Combined Inhibition of Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling in Non Small Cell Lung Cancer Therapy. Clinical Lung Cancer, 10, S17-S23.  
&lt;br&gt;http://dx.doi.org/10.3816/CLC.2009.s.003</mixed-citation></ref><ref id="hanspub.17069-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">西安知先信息技术有限公司. 肺癌的靶向治疗时代已来临[J]. 第三军医大学学报, 2014(3): 193.</mixed-citation></ref><ref id="hanspub.17069-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">周严, 韩宝惠. 靶向治疗时代下的非小细胞肺癌化疗现状与进展[J]. 上海医药, 2015(15): 9-13.</mixed-citation></ref><ref id="hanspub.17069-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">赵颖, 王芮, 付桂英. 非小细胞肺癌分子靶向治疗药物的研究进展[J]. 实用临床医药杂志, 2014, 18(1): 140-142.</mixed-citation></ref><ref id="hanspub.17069-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Fukuoka, M., Yano, S., Giaccone, G., et al. (2003) Multi-Instiutional Randomized Phase II Trail of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 21, 2237-2246.  
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2003.10.038</mixed-citation></ref><ref id="hanspub.17069-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Mollberg, N., Surati, M., Demchuk, C., et al. (2011) Mind-Mapping for Lung Cancer: Toward a Personalized Therapeutics Approach. Advances in Therapy, 28, 173-194. &lt;br&gt;http://dx.doi.org/10.1007/s12325-010-0103-9</mixed-citation></ref><ref id="hanspub.17069-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">倪子俞. 谈肺癌的靶向治疗[J]. 临床肺科杂志, 2010, 15(4): 451-452.</mixed-citation></ref><ref id="hanspub.17069-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">满韦韬, 黄泳. 晚期非小细胞肺癌的靶向治疗研究进展[J]. 中国癌症杂志, 2010, 20(4): 308-311.</mixed-citation></ref><ref id="hanspub.17069-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">蔡智慧, 张翠英. 肺癌的分子靶向治疗进展[J]. 西部医学, 2014, 26(1): 122-123.</mixed-citation></ref><ref id="hanspub.17069-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Johnson, D.H., Fehrenbiicher, L., Novotny, W.F., et al. (2004) Randomized Phase II Trial Comparing Bevacizumab plus Car-boplatin and Paclitaxel with Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Journal of Clinical Oncology, 22, 2184-2191.  
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2004.11.022</mixed-citation></ref><ref id="hanspub.17069-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Reck, M., Von Pawel, J., Zatloukal, P., et al. (2009) Phase III Trial of Cisplatin plus Gemcitabine with Either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer: AVAiI. Journal of Clinical Oncology, 27, 1227-1234. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2007.14.5466</mixed-citation></ref><ref id="hanspub.17069-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Heist, R.S., Fidias, P., Huberman, M., et al. (2008) A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 3, 1153-1158. 
&lt;br&gt;http://dx.doi.org/10.1097/JTO.0b013e318187273f</mixed-citation></ref><ref id="hanspub.17069-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">王艇, 罗黎力. 贝伐单抗治疗晚期非小细胞肺癌的系统评价[J]. 中国实用医药, 2008, 3(5): 1-2.</mixed-citation></ref><ref id="hanspub.17069-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">薛聃, 周彦斌. 非小细胞肺癌分子靶向药物的研究进展[J]. 国际内科学杂志, 2008, 35(7): 419-422.</mixed-citation></ref><ref id="hanspub.17069-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">耿丽, 王瑞. 恩度联合培美曲塞方案二线治疗晚期非小细胞肺癌临床观察[J]. 医药论坛杂志, 2011, 32(12): 63- 65.</mixed-citation></ref><ref id="hanspub.17069-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">郑青平, 倪秉强, 伍美娟, 罗平, 罗展雄, 张志红, 徐艺安. 肝癌放疗前后血浆VEGF表达的临床意义[J]. 重庆医学, 2010, 39(3): 288-289.</mixed-citation></ref><ref id="hanspub.17069-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">王洋, 梁岳培. 抗VEGF和抗EGFR靶向治疗非小细胞肺癌的研究进展[J]. 临床医学工程, 2011, 18(2): 312-313.</mixed-citation></ref><ref id="hanspub.17069-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hirsch, F.R., Varella-Garcia, M., Bunn Jr., P.A., et al. (2003) Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation between Gene Copy Number and Protein Expression and Impact on Prognosis. Journal of Clinical Oncology, 21, 3798-3807. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2003.11.069</mixed-citation></ref><ref id="hanspub.17069-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">刘赞, 郭丽丽, 唐俊舫, 等. 吉非替尼治疗晚期非小细胞肺癌临床疗效分析[J]. 中国临床医生, 2011, 39(7): 29- 31.</mixed-citation></ref><ref id="hanspub.17069-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kris, M.G., Natale, R.B., Herbst, R.S., et al. (2003) Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer Randomized Trail. JAMA, 290, 2149-2158. &lt;br&gt;http://dx.doi.org/10.1001/jama.290.16.2149</mixed-citation></ref><ref id="hanspub.17069-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Fukuoka, M., Yano, S., Giaccone, G., et al. (2003) Mul-ti-Institutional Randomized Phase II Trail of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 21, 2237-2246. 
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2003.10.038</mixed-citation></ref><ref id="hanspub.17069-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Sequist, L.V., Martins, R.G., Spigel, D., et al. (2008) First-Line Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring Somatic EGFR Mutations. Journal of Clinical Oncology, 26, 2442-2449. 
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2007.14.8494</mixed-citation></ref><ref id="hanspub.17069-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, J.Q., Zhong, W.Z., Zhang, G.C., et al. (2008) Better Sur-vival with EGFR Exon 19 than Exon 2 Mutations in Gefltinlb-Treated Non-Small Cell Lung Cancer Patients Is Due to Differential Inhibition of Downstream Signals. Cancer Letters, 265, 307-317. &lt;br&gt;http://dx.doi.org/10.1016/j.canlet.2008.02.064</mixed-citation></ref><ref id="hanspub.17069-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Akeriey, W., Boucher, K.M., Bentz, J.S., et al. (2009) A Phase II Study of Erlotinib as Initial Treatment for Patients with Stage B-IV Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 4, 214-219. 
&lt;br&gt;http://dx.doi.org/10.1097/JTO.0b013e3181943bb9</mixed-citation></ref><ref id="hanspub.17069-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Costa, D.B., Nguyen, K.S., Cho, B.C., et al. (2008) Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinb. Clinical Cancer Research, 14, 7060-7067.  
&lt;br&gt;http://dx.doi.org/10.1158/1078-0432.CCR-08-1455</mixed-citation></ref><ref id="hanspub.17069-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">彭培建, 林忠, 张红雨, 等. 厄洛替尼治疗晚期非小细胞肺癌患者的疗效及安全性研究[J]. 中国全科医学, 2010, 13(13): 1420-1423.</mixed-citation></ref><ref id="hanspub.17069-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">陈志城. 厄洛替尼及其有关热点问题[J]. 中国处方药, 2005(4): 70-72.</mixed-citation></ref><ref id="hanspub.17069-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Herbst, R.S., Prager, D., Hermann, R., et al. (2005) TRIBUTE: A Phase Ⅲ Trial of Erlotinib Hydrochloride (OSI2774) Combined with Carbop Latin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 23, 5892-5899. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2005.02.840</mixed-citation></ref><ref id="hanspub.17069-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">汪琪琪, 郭文浩, 王晓华, 等. 西妥昔单抗治疗晚期肥效细胞肺癌的研究进展[J]. 华西医学, 2006, 21(3): 663- 664.</mixed-citation></ref><ref id="hanspub.17069-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Belani, C.P., Schreeder, M.T., Steis, R.G., et al. (2008) Cetuximab in Combination with Carboplatin and Docetaxel for Patients with Metastatic or Advanced-Stage Non-Small Cell Lung Cancer: A Multicenter Phase 2 Study. Cancer, 113, 2512-2517. &lt;br&gt;http://dx.doi.org/10.1002/cncr.23902</mixed-citation></ref><ref id="hanspub.17069-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Pirker, R. (2008) Cetuximab: Potential Role as First Line Treatment for Advanced Non-Small Cell Lung Cancer. Clinical Advances in Hematology &amp; Oncology, 6, 735-736.</mixed-citation></ref><ref id="hanspub.17069-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">黄晓慧. 非小细胞肺癌的多靶点联合靶向治疗进展[J]. 现代中西医结合杂志, 2013, 22(12): 1363-1365.</mixed-citation></ref><ref id="hanspub.17069-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Stewart, D.J. (2008) Design of Phase II Cancer Trials Using a Continuous End Point of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 100, 445-446. &lt;br&gt;http://dx.doi.org/10.1093/jnci/djn021</mixed-citation></ref><ref id="hanspub.17069-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Ping, G., Wang, H.-M., Wang, W.-M., et al. (2011) Stmitinib in Pretreated Advanced Non-Small-Cell Lung Carcinoma: A Primary Result from Asian Population. Medical Oncology, 28, 578-583.  
&lt;br&gt;http://dx.doi.org/10.1007/s12032-010-9500-9</mixed-citation></ref><ref id="hanspub.17069-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">周爱萍. 多靶点抗肿瘤药物舒尼替尼研究进展[J]. 药物与临床, 2009, 7(1): 48-52.</mixed-citation></ref><ref id="hanspub.17069-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Socinski, M.A., Novello, S., Brahmer, J.R., et al. (2008) Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small Cell Lung Cancer. Journal of Clinical Oncology, 26, 650-656. 
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2007.13.9303</mixed-citation></ref><ref id="hanspub.17069-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Nlovello, S., Scagliotti, G.V., Rosell, R., et al. (2009) Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Journal of Cancer, 101, 1543-1548. 
&lt;br&gt;http://dx.doi.org/10.1038/sj.bjc.6605346</mixed-citation></ref><ref id="hanspub.17069-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Morabito, A., Piccirillo, M.C., Falasconi, F., et al. (2009) Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions. Oncologist, 14, 378-390. &lt;br&gt;http://dx.doi.org/10.1634/theoncologist.2008-0261</mixed-citation></ref><ref id="hanspub.17069-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">李梦君, 涂超, 贺洁宇, 等. 凡德他尼治疗晚期非小细胞肺癌的Meta分析[J]. 肿瘤药学, 2012, 2(5): 385-391.</mixed-citation></ref><ref id="hanspub.17069-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Nlatale, R.B., Bodkin, D., Govindan, R., et al. (2009) Vandetanib versus Gefitinib in Patients with Advanced Non- Small Cell Lung Cancer Results from a Two-Part, Double-Blind, Randomized Phase II Study. Journal of Clinical Oncology, 27, 2523-2529. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2008.18.6015</mixed-citation></ref></ref-list></back></article>